Pharmaceuticals

A new oral drug candidate for lupus and RA emerges as Totus Medicines uses its AI platform to rapidly develop a first-in-class inhibitor for the elusive IRF5 protein.

Biopharma veteran Glenn Gormley joins Aktis's board, bringing deep ADC expertise to guide the company's next-gen radiopharmaceutical pipeline.

A novel drug for a debilitating stomach disorder is set for a major reveal, offering hope to millions with limited and often risky treatment options.

A new survey shows nearly half of employers are considering international drug sourcing, a legally murky strategy, as cost control dethrones talent retention.

GC Biopharma's new data on ALYGLO's purity profile could set a new standard for IVIG therapies, impacting patient safety in a rapidly growing market.

A new partnership combines live biopsy analysis with agentic AI, seeking to predict immunotherapy response and solve why only 1 in 5 patients benefit.

A Boston biotech says its new AI platform moves beyond correlation to find the true biological causes of disease, promising a new era for medicine.

With a massively oversubscribed €600M hybrid note offering, plant-based leader Roquette secures major funding and a huge vote of investor confidence.

A novel immunotherapy tames a potent but toxic cancer-fighting agent by locking it inside tumors, offering new hope for patients with resistant cancers.

A new AI platform is revolutionizing how pharma creates complex scientific videos, earning industry award recognition for its speed, savings, and compliance.

A new oral therapy shows a 76% response rate in a hard-to-treat lung cancer, offering a powerful new first-line option for patients with this rare disease.

Biopharma leader Dr. Gavin Barnard joins ATUM as CSO, aiming to leverage AI and advanced tech to fast-track complex therapies from the lab to the clinic.

With founder Frédéric Mascha as Executive Chairman and new CEO Renaud Sermondade, Juvisé Pharmaceuticals is poised for major M&A-fueled global expansion.

Inventia Life Science's new RASTRUM Validated Solutions offer standardized 3D models to tackle the reproducibility crisis in pharmaceutical R&D.

A Chinese biotech has won a key approval for a novel antibody designed to fight deadly leukemias with enhanced safety, marking a new frontier in cancer care.

A new partnership integrates expert rater training with eCOA tech, aiming to reduce costly data errors and accelerate development of new neurological drugs.

With key advisory appointments, NeuraClick aims to overcome long-standing hurdles in peptide drug development for complex brain and metabolic disorders.

With 62 profitable quarters and a major new acquisition, BioSyent prepares to pitch its proven growth strategy to top healthcare investors in Toronto.

A new biotech player is advancing a first-in-class cancer drug that combines two payloads to fight tumors that have become resistant to current therapies.

Backed by Bain Capital and a veteran team, the new biotech has a de-risked pipeline from Bristol Myers Squibb aimed at transforming care for lupus and more.